Ann: Broker Research Report , page-9

Lionel: 8 days back,PW re-affirmed to me that PYC remained on track with their deal negotiations. I am currently buying, in anticipation of a very strong 4mths.
..............

I think it's worth highlighting some powerful 3rd party quotes concerning PYC, that are worth a thousand pages of NW spin:

"We scour the world looking for innovation that could lead to new medicines, and our collaboration with Phylogica has uncovered an exciting area of research.."....Dr Anton Haselbeck, Head of New Technologies in Roche's Pharma Research & Early Development unit.

"..In the past year we have established a research collaboration with Perth-based Phylogica. This partnership underscores our commitment to finding partners in Australia with novel technology platforms as well as therapies that could lead to the next step-change in medicine."....Stella Xu, Executive Director for Roche Partnering.

"I am excited to be transitioning our collaboration with Phylogica into a commercial operation. We have shown that the enormous structural diversity of Phylomer libraries can be harnessed in phenotypic screens that can identify and validate new targets for drug discovery with high efficiency."....Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research at the University of Cambridge, who directs the molecular therapeutics programme and the MRC Cancer Cell Unit in the Hutchison/MRC Research Centre.
.........
ST